Moderna's stock plunges in premarket trading as Bancel promises company is in 'much better place' for FY23 deliveries
Moderna’s stock plunged more than 11% in premarket trading on Thursday as CEO Stéphane Bancel reported a drop in Covid sales and lowered his full-year sales expectations.
The chief executive now expects $18 billion to $19 billion in sales this year — as opposed to a previously anticipated $21 billion — due to delivery delays, short-term supply shortages and a “very complex third quarter from a manufacturing standpoint.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.